Maiway Biotechnology (688062.SH) announced its first-quarter results, with a net loss attributable to shareholders of 292 million yuan.

China Fortune Financial News app reported that Maiweisheng Biology (688062.SH) released its first quarter report for 2025. During the reporting period, the company achieved revenue of 44.79 million yuan, a year-on-year decrease of 33.70%. The net loss attributable to shareholders was 292 million yuan, and the non-GAAP net loss was 293 million yuan. The basic earnings per share was -0.73 yuan.